@iamalexissolia's anti-androgen claims need context

What did @iamalexissolia actually say?

The creator argued that testosterone levels need to fall within a "healthy female range" for feminization and chest growth to progress, citing a range of "0.2 to 2.4 nanomoles" per liter. They claimed that levels too low can push someone into what they called "menopause mode," causing hot flushes, night sweats, and mood instability. Levels too high, they said, stall fat redistribution and soften no features. They framed anti-androgens as the tool to hit that optimal window, and teased a follow-up video on spironolactone.

The core message: testosterone suppression is not a binary on/off switch, and blind suppression without monitoring can backfire. That framing is broadly reasonable, and it is something many providers underemphasize in clinical practice.

Does the science back this up?

Mostly, yes, with some important caveats. The Endocrine Society's 2017 clinical practice guidelines for transgender women recommend maintaining serum testosterone below 1.7 nmol/L, which roughly aligns with the upper end of the range cited. The 0.2 to 2.4 nmol/L window the creator references is close to published reference ranges for cisgender women, though lab-specific ranges vary and some set the upper limit lower.

On the "menopause mode" claim: this is real physiology. When both testosterone and estradiol drop simultaneously, the result mirrors hypoestrogen states seen in menopause. Davidge-Pitts et al. (2019, Journal of Clinical Endocrinology and Metabolism) documented that inadequate estradiol alongside aggressive androgen suppression produces vasomotor symptoms and mood dysregulation in transgender women. The hot flushes and emotional dysregulation the creator describes are consistent with this evidence.

The idea that testosterone contributes to libido, mood, and skin integrity is also supported. Davis et al. (2019, The Lancet Diabetes and Endocrinology) reviewed testosterone's role in women and confirmed associations with sexual function and general wellbeing even at low physiological levels.

What did they get wrong (or right)?

They got the conceptual framework right: optimizing both estradiol and testosterone, rather than just hammering testosterone to zero, reflects current clinical thinking. Credit where it is due.

Where the video gets sloppy is in the specificity. The creator says people "tend to fall within the range of not 0.2 to 2.4 nanomoles" but does not specify the unit clearly enough for a lay audience, and never mentions that estradiol levels matter just as much in this equation. Someone watching this could come away thinking testosterone management alone drives feminization outcomes, which is an incomplete picture. Estradiol dosing, receptor sensitivity, and time on therapy are all variables that shape outcomes (Deutsch, 2016, UCSF Transgender Care Guidelines).

The comment that a "little bit of testosterone helps to keep your skin good" is technically defensible but vague enough to mislead. Androgens at high levels are associated with sebaceous gland activity and acne. The nuance here matters and the video skips it entirely.

What should you actually know?

If you are on feminizing hormone therapy and feel like progress has stalled, getting a full hormone panel that includes estradiol, total testosterone, free testosterone, and sex hormone-binding globulin is the starting point. Not just one number.

Anti-androgens are not interchangeable. Spironolactone, bicalutamide, and GnRH analogues each have different mechanisms, side effect profiles, and monitoring requirements. Spironolactone, for instance, affects potassium levels and blood pressure in ways that require regular bloodwork (Hamidi et al., 2011, Journal of Sexual Medicine). Bicalutamide does not suppress testosterone production but blocks androgen receptors, which changes the monitoring picture entirely.

The "menopause mode" warning the creator gives is legitimate and underdiscussed. Providers who only monitor testosterone without checking estradiol can leave patients symptomatic and stalled. If you are experiencing hot flushes, poor sleep, or emotional dysregulation on feminizing HRT, ask your provider to check your estradiol level, not just your testosterone.

• Reference range for testosterone in cisgender women: typically 0.2 to 1.7 nmol/L depending on the lab.
• Endocrine Society recommends testosterone below 1.7 nmol/L for transgender women on HRT.
• Symptoms of combined low testosterone and low estradiol overlap significantly with surgical menopause.